Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma By Ogkologos - July 9, 2026 57 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SUCCESSOR-2 study Source RELATED ARTICLESMORE FROM AUTHOR Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors Combining 177Lu-PSMA-617 with ADT Plus ARPI Prolongs rPFS in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-Naive/Sensitive Prostate Cancer EMA Recommends Extension of Therapeutic Indications for Cetuximab MOST POPULAR Adding Cadonilimab to First-Line Standard Chemotherapy Significantly Improves PFS and OS... November 15, 2024 Finding Hope During Cancer and Pregnancy: “Your Stories” Podcast December 2, 2020 ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... November 11, 2025 To My Fellow Nurses May 13, 2021 Load more HOT NEWS SBRT Emerging as an Important Treatment for Early-Stage Kidney Cancer Final Results of the Collaborative EORTC/Intergroup Randomised Phase III Study of... The US National COVID Cohort Collaborative Consortium Provides Real-World Evidence on... Cancer Immunotherapy Drug Simultaneously Targets Two Proteins that Block Immune Response
